Additional functional studies will be necessary to understand how changes in FA oxidation, lipogenesis, as well as FA uptake and secretion, contribute to reductions in hepatic TAG following PLIN2 loss during NAFLD progression. The gene discussed is PLIN2; the disease is metabolic dysfunction-associated steatotic liver disease.